Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 2/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.36 |
| ▸ | RELA | Q04206 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5898780 | 1.00 | NFKB1 (0.36) | NFKB1NFKB2RELATP53MAPT | |
| SCHEMBL5898732 | 0.84 | NFKB1 (0.31) | NFKB1NFKB2RELAMAPK1 | |
| SCHEMBL5898759 | 0.75 | PSEN1 (0.45) | MAPTHSD17B10MAPK1ATMKMT2A | |
| SCHEMBL6322500 | 0.70 | ELANE (0.32) | — | |
| SCHEMBL5898744 | 0.65 | ESR1 (0.34) | TP53LMNAKMT2A | |
| SCHEMBL26097774 | 0.65 | MAPK1 (0.36) | MAPTMAPK1HTTATMKMT2A | |
| SCHEMBL311575 | 0.62 | LMNA (0.55) | MAPTALOX15MAPK1HTTLMNA | |
| SCHEMBL312623 | 0.62 | LMNA (0.55) | MAPTALOX15MAPK1HTTLMNA | |
| SCHEMBL29807411 | 0.62 | — | — | |
| SCHEMBL5492828 | 0.62 | PREP (0.36) | NFKB1NFKB2RELAMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060069091-A9 | Oxazinones and methods for their use and synthesis | CHIROLOGIX PHARMACEUTICALS, INC. | 2006-03-30 | — | — | US | disclosed |
| US-20050124612-A1 | Oxazinones and methods for their use and synthesis | CHIROLOGIX PHARMACEUTICALS, INC. | 2005-06-09 | — | — | US | disclosed |
| US-6861416-B2 | Oxazinones and methods for their use and synthesis | CHIROLOGIX PHARMACEUTICALS, INC. (CA) | 2005-03-01 | — | — | US | disclosed |
| US-20040023956-A1 | New intermediates and synthetic methods for the stereospecific synthesis of oxazinone compounds, which are useful, for example, as antibiotics. The invention also pertains to novel olefinic oxazinone compounds, methods for | CHIROLOGIX PHARMACEUTICALS, INC (CA) | 2004-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069091-A9 | Oxazinones and methods for their use and synthesis | DHPS, COASY, SQLE | NFKB1 2091/4885NFKB2 3158/4885RELA 2052/4885 |
| US-20050124612-A1 | Oxazinones and methods for their use and synthesis | DHPS, COASY, SQLE | NFKB1 2091/4885NFKB2 3158/4885RELA 2052/4885 |
| US-20040023956-A1 | New intermediates and synthetic methods for the stereospecific synthesis of oxazinone compounds, which are useful, for example, as antibiotics. The invention also pertains to novel olefinic oxazinone compounds, methods for | SQLE, DHPS, COASY | NFKB1 1966/4885NFKB2 3141/4885RELA 2099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.